Figure 6.
Fos eRNA1 is necessary for Fos mRNA expression in neurons. (A) Anti-sense oligonucleotide (ASO) targeting of Fos eRNA1 for 24 h decreased both eRNA1 and Fos mRNA (unpaired t-test t(10) = 20.69, P < 0.0001 and t(10) = 5.739, P = 0.0002), but did not alter eRNA levels from other Fos enhancers (unpaired t-test for Gapdh mRNA t(10) = 0.9696, P = 0.3551; eRNA2 t(10) = 0.8608, P = 0.4095; eRNA3 t(10) = 1.014, P = 0.3346). (B) Fos mRNA targeting ASOs decreased Fos mRNA (t(10) = 5.198, P = 0.0004) with no significant effect on eRNA levels (unpaired t-test for Gapdh mRNA t(10) = 3.744, P = 0.0038; eRNA1 t(10) = 2.056, P = 0.0668; eRNA2 t(10) = 0.6508, P = 0.5298; eRNA3 t(10) = 1.679, P = 0.124). (C) Fos eRNA1 ASO pretreatment for 24 h prior to 1 h Veh treatment or KCl stimulation reduced induction of eRNA1 (top) and mRNA (bottom) when compared to a scrambled ASO control (n = 9 per group, two-way ANOVA for eRNA1 F(1,32) = 154.4 P < 0.0001, for mRNA F(1,32) = 5.267, P = 0.0284). Data expressed as mean ± s.e.m. Multiple comparisons, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
